Navigation Links
Cancer risk found for long-term hormone therapy
Date:8/11/2010

Using postmenopausal hormone therapy for more than 15 years increases a woman's risk of developing breast cancer, particularly among leaner women according to research at the Keck School of Medicine of the University of Southern California (USC).

An analysis of the California Teachers Study focused on postmenopausal hormone therapy use among more than 55,000 women for nearly 10 years. The research was conducted by a team including first author Tanmai Saxena, an M.D. Ph.D student at the Keck School. The research was published today in Cancer Epidemiology, Biomarkers and Prevention, an American Association for Cancer Research journal.

Compared with women who never used postmenopausal hormone therapy, women who used estrogen therapy for more than 15 years were at a 19 percent increased risk of breast cancer. The risk was even more pronounced for women who used combined therapy with estrogen plus progestin for 15 or more years. These women had an increased risk of 83 percent, Saxena said.

"This study shows that there needs to be a personalized conversation with women about the risks of using postmenopausal hormone therapy," said Saxena. "Different women appear to have different risks from hormones."

Thinner women who go on hormone therapy also appear to be at higher risk, Saxena said.

The research revealed that body mass index (BMI) may be an indicator of breast cancer risk for women who use postmenopausal hormone therapy. Women with a BMI of 30 or less appear to be at increased risk of breast cancer from combined therapy, while women with a BMI of 30 or higher were at less risk. Women with a BMI of 25 or less were at the highest risk.

The purpose of the study was to elaborate on the Women's Health Initiative findings regarding the effects of postmenopausal hormone therapy on breast cancer risk. The 15-year WHI, conducted by the National Institutes of Health, was halted in 2002 after increased risks of cardiovascular disease and breast cancer were found among women who were taking combination therapy as part of the trial. This study looked at the risk associated with particular formulations of combination hormone therapy as well as the subtypes of breast cancer resulting.


'/>"/>

Contact: Leslie Ridgeway
leslie.ridgeway@usc.edu
323-442-2823
University of Southern California
Source:Eurekalert

Related biology news :

1. Breast cancer treatment resistance linked to signaling pathway
2. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
3. The dietary supplement genistein can undermine breast cancer treatment
4. Saliva proteins could help detection of oral cancer
5. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
6. Breakthrough optical technology to assess colon cancer risk, accuracy
7. Breast cancer cells recycle to escape death by hormonal therapy
8. Nanodiamond drug device could transform cancer treatment
9. Second lumpectomy for breast cancer reduces survival rates
10. Study looks at psychological impact of gene test for breast cancer
11. SNM releases new fact sheet on breast cancer and molecular imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
Breaking Biology Technology: